FDA — authorised 18 March 2022
- Application: BLA761234
- Marketing authorisation holder: BRISTOL MYERS SQUIBB
- Local brand name: OPDUALAG
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
🇺🇸 Nivolumab + Relatlimab in United States
FDA authorised Nivolumab + Relatlimab on 18 March 2022
Marketing authorisation
Other Oncology approved in United States
Frequently asked questions
Is Nivolumab + Relatlimab approved in United States?
Yes. FDA authorised it on 18 March 2022.
Who is the marketing authorisation holder for Nivolumab + Relatlimab in United States?
BRISTOL MYERS SQUIBB holds the US marketing authorisation.